Nasdaq has delisted ABVE due to failure to file audited statements, with trading suspended June 2, 2026. The company may appeal and pursue OTC quotation ABVEE, but liquidity and price could remain pressured in the near term. Investors should monitor the relisting timeline and any regulatory hurdles affecting a potential merger with Palm Global.
Delisting from Nasdaq typically triggers sharp initial price declines and liquidity loss; OTC listings offer limited liquidity relief and higher trading frictions; historical delistings of US-listed microcaps often lead to extended price weakness absent a timely relisting and clear path to profitability.
Near-term downside risk as Nasdaq delisting unfolds; potential OTCABVEE relief but limited liquidity relief.
Category fits Legal/Regulatory with corporate governance implications; delisting drives immediate liquidity risk and strategic options (appeal, OTC listing, potential M&A).